Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic ...

When Google Research unveils something with the prefix “DS,” you know it’s about data. But DS-STAR, short for Data Science State-of-the-Art Reasoning agent, is more than just another AI experiment. It ...

Understanding the properties of different materials is an important step in material design. X-ray absorption spectroscopy ...

Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% ...

WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated ...

Capricor Therapeutics, Inc. ( CAPR) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Third Quarter 2025 Conference ...

On one hand, we need raw materials such as copper for the transition to climate-friendly technologies, but on the other hand, ...

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

Verrica Pharmaceuticals (VRCA) announced the presentation of new data from its Phase 2 study evaluating VP-315, a novel oncolytic peptide ...

Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases (AASLD), ...

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar ...

Background Pulsed field ablation (PFA) has emerged as a promising non-thermal alternative to conventional atrial fibrillation ...